MedTrace Logo

Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

NCT02587364 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-04-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the multiple-dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.

Conditions

Interventions

DRUG

Gemcabene 50 mg

Gemcabene 50 mg once daily (QD)

DRUG

Gemcabene 150 mg

Gemcabene 150 mg once daily (QD)

DRUG

Gemcabene 450 mg

Gemcabene 450 mg once daily (QD)

DRUG

Gemcabene 750/600 mg

Gemcabene 750/600 mg once daily (QD)

DRUG

Gemcabene 900 mg

Gemcabene 900 mg once daily (QD)

DRUG

Placebo

Placebo once daily (QD)

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-04-30
Primary Completion
1999-09-30
Completion
1999-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02587364 on ClinicalTrials.gov